AQR Capital Management LLC Grows Stock Holdings in AMNEAL PHARMACEUTICALS, INC. $AMRX

AQR Capital Management LLC increased its stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) by 121.3% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 745,475 shares of the company’s stock after purchasing an additional 408,677 shares during the period. AQR Capital Management LLC owned approximately 0.24% of AMNEAL PHARMACEUTICALS worth $6,247,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of AMNEAL PHARMACEUTICALS by 5,975.0% during the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company’s stock valued at $26,000 after purchasing an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of AMNEAL PHARMACEUTICALS during the first quarter valued at approximately $31,000. Amalgamated Bank raised its holdings in shares of AMNEAL PHARMACEUTICALS by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after purchasing an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of AMNEAL PHARMACEUTICALS during the fourth quarter valued at approximately $52,000. Finally, Xponance Inc. raised its holdings in shares of AMNEAL PHARMACEUTICALS by 16.1% during the first quarter. Xponance Inc. now owns 13,183 shares of the company’s stock valued at $110,000 after purchasing an additional 1,828 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group assumed coverage on shares of AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a “buy” rating and a $12.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $11.60.

Insider Activity

In other AMNEAL PHARMACEUTICALS news, Director John Kiely sold 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the transaction, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. This represents a 12.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the transaction, the executive vice president owned 152,426 shares of the company’s stock, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 609,206 shares of company stock valued at $5,700,625. Company insiders own 26.56% of the company’s stock.

AMNEAL PHARMACEUTICALS Trading Down 0.9%

Shares of AMRX stock opened at $10.00 on Friday. AMNEAL PHARMACEUTICALS, INC. has a 12 month low of $6.68 and a 12 month high of $10.34. The stock has a market cap of $3.14 billion, a P/E ratio of 1,001.00 and a beta of 1.19. The company has a 50 day simple moving average of $8.83 and a two-hundred day simple moving average of $8.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities analysts forecast that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current year.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.